Cargando…

Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors

Dryopteris crassirhizoma rhizomes are used as a traditional medicine in Asia. The EtOAc extract of these roots has shown potent xanthine oxidase (XO) inhibitory activity. However, the main phloroglucinols in D. crassirhizoma rhizomes have not been analyzed. Thus, we investigated the major constituen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuk, Heung Joo, Kim, Ji-Yul, Sung, Yoon-Young, Kim, Dong-Seon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796287/
https://www.ncbi.nlm.nih.gov/pubmed/33383880
http://dx.doi.org/10.3390/molecules26010122
_version_ 1783634646554116096
author Yuk, Heung Joo
Kim, Ji-Yul
Sung, Yoon-Young
Kim, Dong-Seon
author_facet Yuk, Heung Joo
Kim, Ji-Yul
Sung, Yoon-Young
Kim, Dong-Seon
author_sort Yuk, Heung Joo
collection PubMed
description Dryopteris crassirhizoma rhizomes are used as a traditional medicine in Asia. The EtOAc extract of these roots has shown potent xanthine oxidase (XO) inhibitory activity. However, the main phloroglucinols in D. crassirhizoma rhizomes have not been analyzed. Thus, we investigated the major constituents responsible for this effect. Bioassay-guided purification isolated four compounds: flavaspidic acid AP (1), flavaspidic acid AB (2), flavaspidic acid PB (3), and flavaspidic acid BB (4). Among these, 1 showed the most potent inhibitory activity with a half-maximal inhibitory concentration (IC(50)) value of 6.3 µM, similar to that of allopurinol (IC(50) = 5.7 µM) and better than that of oxypurinol (IC(50) = 43.1 µM), which are XO inhibitors. A comparative activity screen indicated that the acetyl group at C3 and C3′ is crucial for XO inhibition. For example, 1 showed nearly 4-fold higher efficacy than 4 (IC(50) = 20.9 µM). Representative inhibitors (1–4) in the rhizomes of D. crassirhizoma showed reversible and noncompetitive inhibition toward XO. Furthermore, the potent inhibitors were shown to be present in high quantities in the rhizomes by a UPLC-QTOF-MS analysis. Therefore, the rhizomes of D. crassirhizoma could be used to develop nutraceuticals and medicines for the treatment of gout.
format Online
Article
Text
id pubmed-7796287
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77962872021-01-10 Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors Yuk, Heung Joo Kim, Ji-Yul Sung, Yoon-Young Kim, Dong-Seon Molecules Article Dryopteris crassirhizoma rhizomes are used as a traditional medicine in Asia. The EtOAc extract of these roots has shown potent xanthine oxidase (XO) inhibitory activity. However, the main phloroglucinols in D. crassirhizoma rhizomes have not been analyzed. Thus, we investigated the major constituents responsible for this effect. Bioassay-guided purification isolated four compounds: flavaspidic acid AP (1), flavaspidic acid AB (2), flavaspidic acid PB (3), and flavaspidic acid BB (4). Among these, 1 showed the most potent inhibitory activity with a half-maximal inhibitory concentration (IC(50)) value of 6.3 µM, similar to that of allopurinol (IC(50) = 5.7 µM) and better than that of oxypurinol (IC(50) = 43.1 µM), which are XO inhibitors. A comparative activity screen indicated that the acetyl group at C3 and C3′ is crucial for XO inhibition. For example, 1 showed nearly 4-fold higher efficacy than 4 (IC(50) = 20.9 µM). Representative inhibitors (1–4) in the rhizomes of D. crassirhizoma showed reversible and noncompetitive inhibition toward XO. Furthermore, the potent inhibitors were shown to be present in high quantities in the rhizomes by a UPLC-QTOF-MS analysis. Therefore, the rhizomes of D. crassirhizoma could be used to develop nutraceuticals and medicines for the treatment of gout. MDPI 2020-12-29 /pmc/articles/PMC7796287/ /pubmed/33383880 http://dx.doi.org/10.3390/molecules26010122 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yuk, Heung Joo
Kim, Ji-Yul
Sung, Yoon-Young
Kim, Dong-Seon
Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors
title Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors
title_full Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors
title_fullStr Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors
title_full_unstemmed Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors
title_short Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors
title_sort phloroglucinol derivatives from dryopteris crassirhizoma as potent xanthine oxidase inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796287/
https://www.ncbi.nlm.nih.gov/pubmed/33383880
http://dx.doi.org/10.3390/molecules26010122
work_keys_str_mv AT yukheungjoo phloroglucinolderivativesfromdryopteriscrassirhizomaaspotentxanthineoxidaseinhibitors
AT kimjiyul phloroglucinolderivativesfromdryopteriscrassirhizomaaspotentxanthineoxidaseinhibitors
AT sungyoonyoung phloroglucinolderivativesfromdryopteriscrassirhizomaaspotentxanthineoxidaseinhibitors
AT kimdongseon phloroglucinolderivativesfromdryopteriscrassirhizomaaspotentxanthineoxidaseinhibitors